Africans are more genetically diverse than all other populations combined. Yet, African DNA makes up less than 2% of genetic research material. 54gene is on a mission to improve our understanding of the human genome so we can advance the quality of healthcare worldwide. Founded in 2019, 54gene is building the world’s first and largest pan-African biobank. They are targeting multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease.
Co founder of 54gene, Dr. Abasi Ene-obong
The Nigerian health startup company 54gene aims to unlock the African genome. According to information on the official website of the company, 54gene will partner with research institutions, hospitals, pharmaceutical and biotechnological companies in Africa to address the challenge of limited diverse genomics data. Which may hold the key to medical discoveries and healthcare solutions.
Based on the deductions from the research findings, the initiative by 54gene must be promoted. Because, it will help save the lives of many African people. Operations of the bank will target multiple disease states including, cancer, cardiovascular diseases and neurodegenerative diseases.
The company currently provides services such as, genetic testing and molecular diagnostics for patients and physicians in order to expand access to precision medicine in Africa. 54gene provides its services within the confines of the laws guiding the sector like the international data privacy laws such as HIPAA and GDPR. Opt-in to the proposed biobank is equally voluntary, which prevents any form of coercion.
Conclusively, the company aims to equilibrate healthcare for people of African descent and also advance the quality of medical care worldwide. 54gene attracted the interest of investors such as, Y Combinator, Fifty Years Ventures, Better Ventures, and KdT ventures whom are helping to promote the project in their various capacities.
